イルミナの経営陣

イルミナに入社する前は、Agilentの上級副社長と、Agilentの市場をリードする分析機器ポートフォリオ、インフォマティクス、細胞解析フランチャイズで構成されるAgilent Life Sciences and Applied Markets Group（LSAG）の社長を務めていました。2014年から2018年までは、AgilentのDiagnostics and Genomics Group（DGG）の社長を務めていました。

Agilentに入社する前は、デンマークのがん診断会社DakoのR&D担当副社長でした。Dakoに入社する前は、Copenhagen Consultancy Company（現Bain & Co）で経営コンサルタントを務めていました。キャリアの初期には、デンマークに拠点を置く研究・防衛アプリケーション開発会社であるCantionの創設者兼最高技術責任者でした。

Thaysen氏は、デンマーク工科大学で物理学のMScとPhDを取得しています。

Steve Barnard, PhD, is Illumina’s Chief Technology Officer. He is responsible for leading Illumina’s research and product development teams in engineering, consumables, applications and customer enablement, user design, and global advanced science. These teams are Illumina’s innovation engine and deliver product excellence in next-generation sequencing platforms and applications to accelerate scientific breakthroughs and translation of genomics to the clinic.

Dr. Barnard joined Illumina in 1998 as the company’s first scientist and fourth employee, holding a variety of leadership positions within Illumina’s R&D organization throughout his distinguished 25+ year tenure. Through critical roles in research and technology development, Barnard contributed significantly to maturing Illumina’s foundational science technologies including synthetic chemistry, protein engineering, surface science, assay research and nanofabrication. He holds more than 100 patents globally and has been published in diverse, industry-leading scientific journals, such as Analytical Chemistry, Nature, Science, and Genome Research, to name a few.

Dr. Barnard has played an integral role in advancing Illumina’s industry-leading products, including the launch of the revolutionary NovaSeq X series. His profound understanding of Illumina’s core technologies is accelerating R&D productivity and efficiency, as well as driving shareholder value.

Todd Christian is Senior Vice President, Services, Arrays, and Genomics Access (SAGA) at Illumina, where he is responsible for the strategy & roadmap development & execution, go-to-market strategy and commercialization of Illumina’s Global Service, micro-array, laboratory service, proteomic, and Clinical portfolio of offerings.

Before joining Illumina, Christian was vice president and general manager of the cell analysis division at Agilent Technologies, Inc. During his time there, he was an integral part of the company’s multi-year growth strategy to expand its position in cell analysis and other high-growth segments of the life sciences, biopharma and diagnostics markets to serve new and existing customers.

Christian is a distinguished leader in the life sciences market, with more than 25 years of experience in the industry. Before joining Agilent, he spent a number of years at both large and small organizations in the life sciences space, including Becton Dickinson, Applied Bioscience, and Guava Technologies.

He holds a Bachelor of Arts from Hamilton College and a variety of executive certificate programs in marketing, program management, and operations. He has recently served on a variety of non-profit boards focused on funding youth education and underserved communities, and actively volunteers with Habitat for Humanity.

As Chief Legal Officer, Julie Coletti has worldwide responsibility for all legal, regulatory, and intellectual property matters; government affairs; and market access. She also serves as Corporate Secretary to the Illumina Board of Directors.

Prior to joining Illumina, Coletti was the Chief Legal and Regulatory Officer and Corporate Secretary at Align Technology, Inc. Before that, Coletti served as Vice President and Global General Counsel of Danaher Corporation’s Dental Platform and as Vice President of Bayer HealthCare and Chief Legal Officer/Corporate Secretary for the MEDRAD, Inc./Bayer Radiology and Interventional Division. 

Coletti brings extensive experience advising boards of directors and executive leaders on a broad range of complex issues, including M&A strategies, litigation, compliance matters, governance, and public policy. She is also recognized for building high-performing teams and fostering cultures of continuous learning, development, and positive change.

Coletti received her J.D. from the University of Pittsburgh and her B.A. in English from Rutgers University. Currently, she serves as an independent director for Fortis Life Sciences and a board member for the Humane Animal Rescue of Pittsburgh.

As Chief Financial Officer (CFO), Ankur Dhingra is responsible for Illumina’s accounting, financial planning and analysis, internal audit, investor relations, tax, and treasury functions.

Prior to joining Illumina, Dhingra served as CFO at Summit Therapeutics – a California-based biopharmaceutical oncology company. He was previously CFO at CareDx, Inc, a molecular diagnostics company focused on the transplant patient journey. Dhingra spent 18 years at Agilent Technologies in a variety of financial and operational leadership roles, including Vice President of Investor Relations and Group CFO for the Life Sciences and Applied Markets Group (LSAG), which consists of Agilent's market leading analytical instrument portfolio, informatics, and cell analysis franchise.

Mr. Dhingra is a Chartered Accountant from The Institute of Chartered Accountants of India.

Mark Field joined Illumina as Chief Information Officer on May 29, 2025, bringing over two decades of experience in leading transformative technology initiatives across the life sciences and healthcare sectors. Prior to this role, he served as Chief Technology Officer at Insulet Corporation, where he was instrumental in the development and launch of the Omnipod® 5, the first tubeless automated insulin delivery system. Under his leadership, Omnipod® 5 achieved significant market success, contributing to Insulet's annual revenue surpassing $2 billion and serving approximately 500,000 patients worldwide.

Before his tenure at Insulet, Field held the position of Chief Technology Officer at Thermo Fisher Scientific. There, he led a global team responsible for IoT-connected device programs, cloud-based scientific services, and e-commerce, overseeing 54 business units. He was pivotal in developing the Thermo Fisher Cloud, a platform that revolutionized data sharing among scientists globally. Field's career also includes 17 years at Oracle Corporation, where he rose to Vice President and successfully led the integration of over 105 acquisitions.

Field holds a Bachelor of Science in Computer Science and a Bachelor of Commerce in Management and Information Systems from the University of Auckland in New Zealand. His extensive experience in regulated medical technology environments and his commitment to patient-centric design make him a valuable addition to Illumina's leadership team. As CIO, Field is poised to drive Illumina's digital transformation efforts, leveraging his global perspective and innovative approach to technology to enhance operational excellence and market leadership.

Eric Green, MD, PhD, is the Chief Medical Officer (CMO) at Illumina. As Illumina’s medical leader, Dr. Green is responsible for guiding global efforts to advance the clinical application of genomics, expand access to precision medicine, and increase diversity in genomic data to improve healthcare for people worldwide.

Prior to joining Illumina, Dr. Green worked at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH) for more than 31 years, serving as the NHGRI Director for his final 15 years. Under his leadership, NHGRI became a driving force in integrating genomics into medicine and public health. Before being appointed as the institute’s director, Dr. Green served multiple other leadership roles within NHGRI, including as the institute’s Scientific Director for nearly a decade and as the founding Director of the NIH Intramural Sequencing Center.

Throughout his multi-decade career, Dr. Green has consistently been at the forefront of genomics, helping transform the field from research-driven discovery to clinical practice. His research and leadership contributions have included playing a prominent role in the Human Genome Project, delivering critical insights into genome structure and function through comparative genomics, identifying multiple human disease genes, and accelerating applications of genomics in healthcare.

Dr. Green earned his MD and PhD from Washington University School of Medicine in 1987.

Pat Leckman is Chief People Officer at Illumina, where she is responsible for all aspects of the company’s HR strategies. Leckman has a successful track record for leading workforce transformation, driving business growth, and creating high-impact teams.

Previously, she worked in dynamic organizations such as Watson Wyatt, NVIDIA, Cisco, and Perot Systems. In her tenure as part of the Illumina Human Resources leadership team, she transformed the Compensation, Benefits, and People Technology functions. She has led international teams that design, contract, and implement agreements and joint ventures. Throughout her career, she has helped clients with business process redesign, vendor assessment, outsourcing, and transition management.

Leckman serves on the board of San Diego Squared, a nonprofit dedicated to empowering underrepresented students in STEM. She earned a master’s in business administration from London Business School and a bachelor’s in communication from Stanford University.

Rami Mehio is the Senior Vice President, General Manager, BioInsight at Illumina. He is responsible for leading the research and development teams for bioinformatics, software, clinical interpretation and AI, as well as managing data partnerships, pharma collaborations, and national genomics initiatives. These teams deliver industry-leading solutions for genomic and multiomic applications, working closely with partners and customers to build, analyze, and monetize large datasets—leveraging them to develop new AI models and advance deep biological insights.

Mehio joined Illumina in 2018 through the acquisition of Edico Genome, where he led the development of the DRAGEN Bio-IT platform. He would later serve as Vice President and Head of Software and Informatics, where he drove Illumina’s software and informatics strategy across the company’s entire product portfolio, include instruments, cloud data platforms, and bioinformatics solutions.

Since joining Illumina, Mehio has played a pivotal role in establishing the company’s informatics offering as a comprehensive, end-to-end suite, including DRAGEN, Emedgene, Illumina Connected Analytics and Illumina Connected Insights products. Other key highlights under his leadership include the development of the COVIDSeq test, processing 500,000 UK Biobank samples, winning the PrecisionFDA challenge, and supporting the launch of NovaSeq, NextSeq 2000, and iSeq 100 sequencers.

Mehio holds both a Master of Science and a Bachelor of Science in Engineering from McGill University, and holds 166 global patents.

Kevin Pegels is Chief of Global Operations for Illumina where he is responsible for the company’s global operations. His organization includes Manufacturing, Supply Chain, Life Cycle Management, Information Technology and Global Facilities and Real Estate teams who are committed to ensure high product quality and customer satisfaction.

Prior to joining Illumina, Pegels spent over 20 years in senior leadership roles leading supply chain and operations organizations for Bayer Healthcare, The Clorox Company, and Levi Strauss. In addition, his experience includes Deloitte Consulting advising companies on supply chain, operations strategy, and process improvement.

Pegels currently serves on the advisory committee for Bio Supply Management Alliance (BSMA) and will join the board of the San Diego Regional EDC. He holds a Bachelor of Science in Chemical Engineering from Cornell University as well as a Master of Business Administration from Harvard Business School.

As Chief Commercial Officer of Illumina, Michael Sullivan is responsible for leading the company’s global commercial organization.

Before joining Illumina, Sullivan was Chief Commercial Officer at Caris Life Sciences, where he oversaw global commercial strategy and operations across the company’s precision oncology portfolio. During his six-year tenure, he played a pivotal role in the company’s growth, helping drive revenue to approximately $1 billion annually and leading the expansion of Caris’ international footprint through strategic market entry initiatives, distributor partnerships, and regional infrastructure development. 

Prior to Caris, Sullivan held senior commercial leadership roles at Roche Diagnostics, Johnson & Johnson’s Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott Diagnostics. 

Throughout his career, Sullivan has led organizations through periods of growth and transformation, helping customers adopt innovative technologies and solutions. He has extensive experience building and scaling commercial functions, developing strategic partnerships, and catalyzing expansion across diagnostics and precision medicine businesses.

Sullivan earned a Bachelor of Business Administration in Marketing from Texas A&M University, where he participated in the Honors Program and played varsity football.

Jakob Wedel is Chief Strategy and Corporate Development Officer at Illumina, leading corporate strategy, partnerships, alliances, and acquisitions. With more than 25 years in top-tier strategy consulting focused on the life science and technology sector, Mr. Wedel brings a wealth of expertise in driving growth and innovation to the company.

Prior to joining Illumina, Wedel was a Senior Partner at Ernst and Young's strategy practice, EY Parthenon, where he played a key role in the global expansion of its life science strategy practice. His leadership in the global life science practice provided him with deep insights into the dynamics of the life science tools, clinical diagnostics and biopharma sectors, and positioned him as a trusted advisor for global industry executives.

Wedel spent more than 20 years at renowned consulting firms McKinsey and Bain & Co. serving life science, diagnostics and pharmaceutical clients in the US and Europe. He co-founded the Nordic strategy firm Qvartz, which grew to 450 professionals before being acquired by Bain.

Wedel attended Aarhus University in Denmark and earned a Master of Science in International Marketing & Management from Copenhagen Business School.

Conor McNamara, CFA, is Head of Investor Relations at Illumina, a role he assumed in September 2025.

Prior to joining Illumina, Conor was an Equity Research Analyst at RBC Capital Markets, where he covered the Life Science Tools & Diagnostics sector, including Illumina. From 2005 to 2021, he held analyst and portfolio manager roles at three investment firms – FrontPoint, Hudson Bay, and Tamarack – where he focused on the life sciences sector. Earlier in his career, Conor worked in investment banking and M&A advisory at Lehman Brothers and Deloitte, and in corporate development at McKesson.

Conor is a Chartered Financial Analyst (CFA) and holds a Bachelor of Arts degree in Economics from Occidental College.